Navigation Links
Dyadic International Reports Third Quarter 2013 Financial Results
Date:11/14/2013

uct related revenues and other strategic partnerships, Dyadic expects 2013 total revenues to increase versus 2012.  Because of the increased non-recurring litigation costs, the Company may break even or generate a small loss for the year.  Net of non-recurring litigation costs, the Company expects to be profitable for 2013.

The financial information contained in this press release should be read in conjunction with the financial statements and related footnotes which have been posted on the OTC market website at http://www.otcmarkets.com/stock/DYAI/filings and on Dyadic's website at http://dyadic.com/investorinfo/financials/.

Conference CallA conference call to discuss third quarter 2013 results is scheduled for 5:00 p.m. Eastern Time on Thursday, November 14, 2013.  The conference call may be accessed by dialing +1 (888) 713-3595 (from the United States or Canada) or +1 (913) 905-3226 (from other countries) five to ten minutes prior to start time and providing the confirmation code 9272553.  A replay of the conference call will also be available on the Dyadic website shortly after the live event.

About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Dyadic trades on the OTC Pink tier of the OTC market. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC market website (www.otcmarkets.com/stock/DYAI/quote).

Cautionary Statement for Forward-Looking StatementsCertain statements contained in this pr
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
2. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
3. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
4. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
5. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
7. Dyadic International Reports 2012 Third Quarter Financial Results
8. 12th U.S. Patent Issued To Dyadic International
9. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
10. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
11. Dyadic International To Present At World Biofuels Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... 13, 2011 PrimeraDx today announced that Jeff Liter ... Development.   "Jeff,s diverse background in all ... to the leadership team," Said Matt McManus, President and ... capabilities of the ICE Plex system in the ...
... a human gene mutation in a patient,s stem cells. ... 12 October, brings the possibility of patient-specific therapies closer ... researchers from the Wellcome Trust Sanger Institute and the ... both cirrhotic liver disease and lung emphysema. Using cutting-edge ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... Sequencing 200 Kit, which enables 200 base pair reads. The ... sequencer that can deliver millions of highly accurate long reads ... after our launch, the speed, simplicity and scalability of ...
Cached Biology Technology:PrimeraDx Appoints Jeff Liter as VP of Corporate Development 2Clean correction of a patient's genetic mutation 2Clean correction of a patient's genetic mutation 3Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 2Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 3Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 4Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 5
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Microbes are everywhere thousands of species are in your mouth, ... in your mouth are mostly harmless as long as you ... gum disease a path into the blood stream. Microbes in ... country are also mostly harmless with some notable exceptions. ...
... from the National Cancer Centre Singapore, Duke-NUS Graduate Medical ... University (Thailand), have made a seminal breakthrough in understanding ... a rare but highly lethal form of liver cancer. ... Tan, Steve Rozen, Irinel Popescu and Vajaraphongsa Bhudhisawasdi, used ...
... the first conference of its 2013-2014 meeting season and ... "Advancing Vaccines in the Genomics Era" at the Windsor ... Grand Challenges in Global Health meeting for that program,s ... Symposia Global Health Series, supported by the Bill & ...
Cached Biology News:Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 2Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 3Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 4Singapore scientists expose molecular secrets of bile duct cancers from different countries 2Singapore scientists expose molecular secrets of bile duct cancers from different countries 3Keystone Symposia launches 2013-14 meeting series with first conference in Rio de Janeiro 2
... These plastic feeding tubes for rodent ... reduce the risk of perforation and trauma. ... hassle of cleaning and the risk of ... 20ga ...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
...
... the 9, 10, 12, and 13 positions. It ... for the quantification of 13(S)-HODE by GC- or ... linoleic acid with plant and mammalian lipoxygenases. It ... tumor cells to the endothelium at concentrations around ...
Biology Products: